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Introduction
During the 1970s, a new infectious disease of pups
characterized by either gastro-enteritis or my-
ocarditis was observed worldwide and the etiolog-
ical agent was identified as canine parvovirus type
2 (CPV 2) (Appel et al., 1979; Burtonboy et al.,
1979). Canine parvovirus is a highly contagious
disease in dogs, characterized by hemorrhagic gas-
troenteritis, vomiting and high temperature.
Though the disease can affect dogs of any age, the
disease is often fatal in pups. The CPV type 2 virus
underwent genetic and antigenic drift to become
CPV type 2a, subsequently to type 2b and type 2c
(Parrish et al., 1991; Buonavoglia et al., 2001;
Nakamura et al., 2004). Incidence of the original
CPV type 2 virus was not reported later and was
replaced with the variant types (2a, 2b and 2c). 
Most of the available vaccines contain attenu-
ated CPV type 2.When in vitro cross neutralization
experiments were performed using CPV 2 vacci-
nated sera against CPV type 2, 2a, 2b and 2c virus,
the neutralization titers were significantly lesser
with heterologous type virus (2a, 2b or 2c) com-
pared to the homologous type 2 virus (Pratelli et
al., 2001; Cavalli et al., 2008).Though the interfer-
ence from maternal antibodies and low antibody
titer were the common factors responsible for vac-
cine failure, antigenic variation between the avail-
able vaccine strains and the prevalent virus types
was also indicated as a possible reason for vaccine
failure (Decaro et al., 2008). However, Spibey et
al. (2008) reported that the CPV type 2 protected
vaccinated dogs against the experimental challenge
with CPV type 2c. The present study was under-
taken to evaluate the antigenic relationships of the
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A study was conducted to characterise the field isolates of canine parvovirus (CPV) and an in vitro cross neutralisation assay
was performed against the vaccinated dog sera. Out of 45 faecal samples processed for virus isolation, 27 samples showed
cytopathic effect (CPE) at first passage, which were confirmed positive by CPV variant types specific PCR. The CPV type
2 was not detected in any of the clinical samples. Of these 27 positive samples only 23 samples showed CPE and were further
confirmed as CPV by haemagglutination inhibition test, ELISA and immuno-chromatographic strip test. Antigenic typing
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19 isolates were typed as CPV 2a. The antigenic typing results obtained using the monoclonal antibodies corroborated the
sequencing results reported by our group earlier. The cross neutralization study with polyclonal sera revealed that the sera
of original antigenic type CPV 2 can neutralize the antigenic variants 2a and 2b effectively. Thus we conclude that the
vaccines containing CPV type 2 virus can be used to immunise the dogs against the prevalent CPV 2a and CPV 2b infection.
A live virus challenge study in dogs may further confirm this observation.
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Indian field canine parvoviral isolates with the
CPV type 2 vaccine strain in vitro. 
Materials and methods
Faecal samples of dogs suspected to have CPV in-
fection were collected from seven states of India.
Genetic and antigenic typing along with cross neu-
tralization study was performed for all the isolates. 
Clinical samples, Cells, sera and reference virus
Virus isolation was performed using faecal sam-
ples, which were collected from dogs having the
clinical symptoms of gastro-enteritis. These sam-
ples were obtained from seven different states of
India (Table 1). A72 cells were procured from
American Type Culture Collection (ATCC) (Uni-
versity Boulevard, Manassas, VA 20110 USA), and
the cell line was used for virus isolation. Type spe-
cific polyclonal sera were raised in CPV sero-neg-
ative dogs using CPV type 2 vaccine strain as well
as inactivated antigens of CPV field isolates, P-24
(CPV 2a, Gene Bank Accession no - DQ182624)
or P-25 (CPV 2b, Gene Bank Accession no -
DQ182625) separately. Type 2 vaccine strain of the
virus was used as positive controls in various as-
says described in this report.
Virus isolation in cell culture
Virus isolation was performed using A72 cells as
per the method described by Pollock (1981) with
some modifications. Briefly, the faecal samples
were diluted (1:10 w/v) in chilled minimum essen-
tial medium (MEM) and homogenized using vortex
mixture. The homogenate was centrifuged at 3000g
for 15 minutes and treated with 0.1% (v/v) chloro-
form. Then, the samples were filtered through 0.2µ
pore size syringe filter. An aliquot of 0.2 ml of the
filtrate was used to inoculate the A72 cell mono-
layer in 25 cm2 flask. The flasks were incubated at
37ºC and were observed for cytopathic effect
(CPE) at 12 hourly intervals. Rounding and detach-
ment of the cells were considered as the indication
of CPE. When the CPE was more than 70%, the
virus was harvested by freeze-thawing the cells. In
the absence of any pronounced CPE, the culture fil-
trates were harvested five days post inoculation. All
the samples were passaged in A72 cells for five
times, irrespective of the presence of CPE. Samples
showing no CPE after five passages were declared
negative for virus.
Virus identification
Presence of CPV in the A72 culture harvest was
identified by Haemagglutination (HA) test using
porcine red blood cells (RBCs). The identification
of the virus was further confirmed by haemagglu-
tination inhibition test using CPV specific poly-
clonal dog sera, immuno-chromatographic strip test
and ELISA.The HA test was performed as de-
scribed by Pollock (1981) in ‘U’ bottom 96 well
microtitrer plate (Laxbro, India). The HA titer was
defined as the reciprocal of highest dilution that
caused haemagglutination as indicated by mat for-
mation.  The tissue culture fluid of fifth passage
harvest, which was positive for HA test with pig
RBC was subjected to haemagglutination inhibi-
tion (HI) test using CPV vaccinated dog sera. The
test was carried out as per the method described by
Pollock (1981). The samples showing complete in-
hibition of haemagglutination activity (no mat for-
mation) were declared as CPV positive. 
Immuno-chromatography test kit, which detects
all the CPV types (IngezimParvocromTM kit- IN-
GENASA, Spain), was used to confirm the virus
from A72 cell culture passages. The test was car-
ried out as per the method described by the manu-
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Table 1. Source of the clinical samples used in the study.
facturer. Briefly, a drop of tissue culture super-
natant was used for the test. Appearance of a purple
line in the test window no: 3 (control line) indicated
the validity of test. Presence of CPV in the sample
was indicated by the appearance of purple line in
test window no: 2. 
All the tissue culture fluid harvests from A72
cell passage were subjected to double antibody
sandwich ELISA (DAS ELISA kit- INGENASA,
Spain) for the identification of CPV. The test was
carried out as per the method suggested by the
manufacture. The absorbance of each well was
recorded by a spectrophotometer at 405 nm. Sam-
ples with OD value higher than the cut off value
were considered positive and samples with OD
value lower than the cut off values were considered
negative.
CPV typing using Polymerase chain reaction
(PCR) 
All the processed clinical samples and tissue cul-
ture fluid harvest from A72 cell passage were sub-
jected to PCR. DNA extraction was carried out
using DNAzol reagent (Invitrogen, USA) follow-
ing the manufacturer’s instructions. The CPV types
were identified from the extracted total DNA using
PCR. Two independent PCRs were performed to
identify CPV2 and its variants. The primer pair
P2s/P2as described by Senda et al. (1995) was used
to identify CPV type 2 whereas primer pairs
Pabs/Pabas described by Pereira et al. (2000) were
used to identify the variant types. The samples
which were positive in Pabs/Pabas PCR were again
subjected to Pbs/Pbas PCR (Pereira et al., 2000) to
identify the CPV type 2b virus.
Antigenic typing
Antigenic typing was carried out for all the CPV
isolates and two reference vaccine strains of CPV
Type 2 (strain 1 and strain 2) using a panel of four
monoclonal antibodies (mAbs; kindly provided by
Dr Y. Tohya, University of Tokyo, Bunkyo-ku,
Tokyo). The HI test was carried out with the mon-
oclonal antibodies against 8 HA units of tissue cul-
ture adapted CPV isolates and reference CPV type
2 virus. The comparative titers were evaluated for
antigenic typing of the virus. Mouse monoclonal
antibody 19D7 detects all the CPV types, mink en-
teritis virus and feline panleukopenia virus. The
virus isolates, which showed high reactivity with
mAbs 21C3, 20G4 and 2G5 were typed as CPV 2b.
The virus isolates having high reactivity with
mAbs 20G4 and 2G5 and less reactivity with mAb
21C3 were typed as CPV 2a. The CPV isolates that
showed low reactivity with mAbs 20G4, 2G5 and
21C3 and high reactivity with mAb 19D7 were
classified as CPV type 2. 
Antigenic characterization by cross neutralization
with specific polyclonal sera
Polyclonal dog sera against CPV type 2, type 2a
and type 2b respectively were prepared as de-
scribed above. All the virus isolates were subjected
to cross reactivity test using the type specific poly-
clonal sera in a HI test. The test was carried out
using 8 HA units of tissue culture adapted CPV iso-
lates. The reciprocal of highest dilution of serum
showing inhibition was considered as HI titer. The
HI titer with homologous as well as heterologous
virus was recorded.
Results
Virus isolation in cell culture
Virus isolation was attempted for 45 faecal samples
collected from different parts of India. After the
first passage in A72 cells, 27 out of 45 samples
showed CPE and on subsequent passages only 23
samples showed distinct CPE such as rounding, de-
velopment of multinucleated cells and detachment
of the cells from monolayer. Similar kind of CPE
was reported earlier also by Pollock (1981). The
HA titer of these samples was ≤ 4 HA units on sec-
ond passage onwards.
Identification of virus
Hemagglutination and HI test
All the 45 samples were subjected to HA test using
porcine RBC’s after every passage on A72 cells.
Samples producing distinct CPE in cell culture also
showed ≥4 HA units/50 µl of the sample. Out of
the 45 samples processed for virus isolation, 27
samples showed titers ≥ 4 HA units per 50µl of tis-
sue culture harvest on first passage (Table 2). The
23 isolates were passaged five times in A72 cells
and HI test was performed on the culture super-
36
Shankar R. Chinchkar et al. /Journal of Advanced Veterinary Research 4 (2014) 34-41
natant of the fifth passage material. The complete
inhibition of haemagglutination activity of all 23
virus isolates was observed using CPV specific
serum (CPV vaccinated dog sera).  The HI titer val-
ues ranged between 128 and 1024 HI units (Table
2). Clear inhibition of HA activity of CPV specific
serum against the virus isolates confirmed the iden-
tity of the isolates as CPV.
Immunochromatography (INGEZIM PARVO
CROM kit) and Double antibody sandwich ELISA
(DAS ELISA): The 23 CPV isolates were further
confirmed in immuno-chromatographic strip test
and double antibody sandwich ELISA (INGEZIM
PARVO CROM kit and DAS ELISA kit). All the
23 isolates tested positive in both the assays and
these results confirmed the isolation of CPV from
clinical material (Table 2).
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Table 2. Identification of CPV isolates using various laboratory tests.27 of the 45 clinical samples were positive
by PCR. Of the 27 samples, virus isolation was successful for 23 samples. The isolates were confirmed using
ELISA, immuno-chromatographic strip test and HI after five passages in A72 cell.
Fig. 1. Gel picture shows the results of PCR with the DNA from few of the tissue culture supernatants. The PCR was performed
with Pabs and Pabas primers to identify the CPV 2 variants -CPV 2a and CPV-2b. 1. Isolate P-1; 2. Isolate P-5;3. Isolate P-
8; 4. Isolate P-14; 5.1 Kb ladder; 6.Isolate P-17; 7. Isolate P-20; 8. Isolate P-25; 9. Negative control.
aAll the 27 isolates were positive when the PCR was performed directly from the clinical material.
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Table 3. Haemagglutination inhibition titersusing type specific monoclonal antibodies.Based on the HI titers, four
of the 23 isolates were typed as CPV 2b and the remaining 19 isolates were typed as CPV 2a. The typing results
using the mAbs matched 100% with that of sequencing results (genetic typing). 
Fig. 2. Gel picture shows the results of PCR using the primer pairs P2s and P2as.This primer pair was used to identify the
CPV type 2. None of the field isolates showed positive amplification and both the vaccine strains were positive in the PCR.1.
Isolate P-1;2. Isolate P-5;3. Isolate P-8; 4. Isolate P-14; 5.Isolate P-17; 6. Isolate P-20; 7. CPV2 vaccine-strain 1; 8.CPV2 vac-
cine-strain 2; 9.Negative control; 10.100 bp ladder.
Virus identification and typing by polymerase
chain reaction
All 45 clinical samples were screened in PCR using
P2s/P2as and Pabs/Pabas primers. We observed
that 27 out of 45 samples produced a band at 680
bp with Pabs/Pabas primers confirming the pres-
ence of CPV variant types in these clinical samples
(Fig. 1). None of the clinical samples produced am-
plicons of designated size with P2s/P2as (Fig. 2).
except CPV type 2 vaccine strains, which was used
as positive control. Our results indicate the absence
of CPV type 2 in the clinical samples; all the virus
isolates were of variant types. Out of the 27 isolates
only 23 samples turned positive when the PCR was
conducted using culture supernatant from the fifth
aChinchkar et al. (2006)
passage material. These 23 samples were subjected
to PCR with CPV 2b specific primers (Pbs/Pbas)
and few of the samples produced a PCR product of
420 bp. However, the 2b specific primers showed
ambiguous results when the PCR was repeated.
Antigenic typing using a panel of monoclonal an-
tibodies
For antigenic typing of the CPV isolates, a panel
of four mAbs (19D7, 21C3, 20G4 and 2G5) were
used. All 23 virus isolates showed equal reactivity 
with mAb 19D7, which confirmed the presence of
CPV in the sample. The reactivity of all isolates
was almost equal with mAbs 20G4 and 2G5, rang-
ing from 6700 to 51200 HI titers. These two mAbs
detects CPV variant types. The reactivity of four
virus isolates was high with mAb 21C3 which de-
tects CPV 2b specifically and the titers were rang-
ing from 12800 to 25600 HI units. The other 19
isolates showed relatively low reactivity (400 to
1600 HI units) with mAb 21C3 and confirmed as
type CPV 2a. Two reference canine parvovirus vac-
cine strains showed very low reactivity with mAbs
21C3, 20G4 and 2G5, whereas the reactivity of the
vaccine strains was high using mAb 19D7. The re-
sults were summarized in Table 3. The antigenic
typing results were on the same line of genetic typ-
ing (Chinchkar et al., 2006).
Antigenic characterization by cross neutralization
with specific polyclonal sera
Cross neutralization of the virus isolates was per-
formed in vitro with six CPV 2a isolates, two CPV 
2b isolates and two reference CPV type 2 vaccine
strains using mono-specific polyclonal serum
against CPV type 2 (vaccine strain), type 2a (P24)
and type 2b (P25). The results were summarized in
Table 4. Monospecific polyclonal serum against
CPV type 2 virus did not show any significant dif-
ference in reactivity with homologous (CPV type
2 strain 1 and strain 2) as well as heterologous
(CPV 2a and CPV 2b) virus types. The HI titers
were ranging from 320 to 1280 HI units. The HI
titers of CPV 2a monospecific polyclonal serum
against CPV 2a and CPV 2b virus isolates did not
vary much (1280 to 5120 HI units). The reactivity
of CPV 2b monospecific polyclonal serum against
CPV 2a and CPV 2b virus isolates was also in a
similar range (640 to 2560 HI units). However, the
CPV 2a and CPV 2b monospecific polyclonal
serum showed low reactivity against type 2 viruses
and the titers were ranging from 40 to 320 HI units,
whereas the reactivity of these sera with homolo-
gous virus were comparatively high (640 to 5120
HI units). 
Discussion
Parvoviral enteritis is one of the fatal diseases af-
fecting pups worldwide. The disease is being con-
trolled using vaccines. The variant types of CPV2
have emerged across the world. Though the variant
types replaced the type 2 virus, most of the com-
mercial vaccines contain the attenuated CPV type
2 strains. 
We were successful in isolating CPV from 23
of the faecal samples of dogs showing enteritis. All
the isolates were verified by HA and HI using CPV
39
Shankar R. Chinchkar et al. /Journal of Advanced Veterinary Research 4 (2014) 34-41
Table 4. Results of the haemagglutination inhibition test using polyclonal sera to study antigenic cross reactivity
between CPV-2, CPV-2a and CPV-2b.
specific sera. The HA and HI tests are routinely
used methods for identification of CPV (Appel et
al., 1979; Helfer-Baker et al., 1980; Kramer et al.,
1980; Pollock, 1981). The HI test is considered to
be the confirmatory test for identification of CPV
virus and it has been used extensively by many in-
vestigators (Appel et al., 1979; Carmichael et al.,
1980; Meunier et al., 1981). The isolates were fur-
ther confirmed by Immunochromatography strip
test and DAS ELISA. 
The isolates were also subjected to PCR ampli-
fication using type specific primers. All the 23 iso-
lates could be detected using primers specific for
CPV variant strains. None of the virus isolated
from the clinical samples were of CPV type 2. Our
results are in agreement with the finding that sug-
gested disappearance of CPV 2 in clinical speci-
mens and replacement with its variant types
(Parrish et al., 1991; Truyen et al., 1996; Steinel et
al., 1998; Chinchkar et al., 2006; Mohan Raj et al.,
2010). However, the PCR with 2b specific primers
produced inconclusive results. The reason for the
ambiguous PCR results with 2b specific primers
was reported by our group earlier with the VP2
gene sequencing (Chinchkar et al., 2006). The
primers in the PCR to differentiate CPV 2a from
CPV 2b are designed based on the nucleotide
changes at position 4062 (A→G) and 4449
(A→G). In general, CPV 2a has nucleotide A at po-
sition 4449 and CPV 2b has G at 4449. However,
all the Indian CPV isolates had G at 4449, irrespec-
tive of the type (Chinchkar et al., 2006). Therefore,
the CPV 2a and CPV 2b isolates had only one base
difference in between them, rendering the PCR
based differentiation difficult. Our work indicated
that the PCR primers (Pereira et al., 2000) are ir-
relevant in differentiating CPV 2a from CPV 2b of
India (Martella et al., 2006; Hariprasad Naidu et
al., 2012). Antigenic typing using a panel of mon-
oclonal antibodies demonstrated that 19 of the iso-
lates were CPV type 2a and 4 of them were type
2b. The antigenic typing results matched 100%
with the genetic typing which was published earlier
(Chinchkar et al., 2006).
Polyclonal serum against CPV type 2 virus re-
acted with homologous (CPV type 2 strain1 and
strain 2) as well as heterologous (CPV 2a and CPV
2b) virus types equally. This is in contrast to the
observation made by Pratelli et al. (2001) and Cav-
alli et al. (2008). They reported significantly lower
HI titer values against variant type viruses for the
type 2 vaccinated dog sera. The CPV 2a and CPV
2b polyclonal serum showed low reactivity against
type 2 viruses. Cavalli et al. (2008) also reported
significantly lower HI titer against CPV 2 com-
pared to the variant types when the sera from CPV
2b vaccinated dogs were tested. 
The in vitro cross neutralization studies revealed
that the sera developed using CPV type 2 virus re-
acted with the antigenic variants also with the HI
titers similar to that of homologous virus. There-
fore, the virus type used in the evaluation of CPV
2 vaccine titer might not influence the HI titer; fur-
thermore, any one of the virus types can be used to
assess the CPV 2 vaccine titer. Though the earlier
reports published using the in vitro neutralisation
tests suggests that the CPV 2 vaccine has lesser
neutralisation titers against the variant types
(Pratelli et al., 2001; Cavalli et al., 2008), our study
did not show any significance difference in the HI
titers using the CPV2 immune sera. Moreover,
Spibey et al. (2008) performed a virus challenge
study in CPV2 vaccinated dogs to conclude that the
vaccine based on CPV2 strains could protect the
dogs against CPV type 2c. Tough the in vitro cross
neutralization study reported in this work indicated
that the current vaccine strain can protect against
prevailing antigenic variant CPV types, this finding
must be confirmed using animal challenge studies.
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